Key liaison with official bodies

 

 

Interlocución clave ante organismos oficiales

Society’s need for reliable, accurate information has made AseBio a key liaison for official bodies:

On 31 January, we sent letters to the Ministry of Health and the Ministry of Science and Innovation offering up the capacities of the Spanish biotechnology sector to tackle the healthcare emergency declared by the World Health Organisation.

On 18 March, we contacted the Directorate-General for Public Health and the Directorate-General of the Basic Portfolio of National Health System and Pharmacy Services offering up the capacities of the Spanish biotechnology sector with regard to the SARS-CoV-2 healthcare emergency.

On 19 March, we notified AseBio members that we had offered up the capacities of the Spanish biotechnology sector to the National Health System.

On 27 March, we sent a detailed list of the capacities, products and services loaned and donated by the Spanish biotechnology sector to tackle the SARS-CoV-2 healthcare crisis to the Directorate-General for Public Health and the Directorate-General of the Basic Portfolio of National Health System and Pharmacy Services.

On 27 March, we notified members of the Inspiration campaign to work in times of the coronavirus, valorising innovative practices and policies for managing our organisations.

On 29 March, AseBio had biotechnology classified as an essential activity under Royal Decree-Law (RDL) of 29 March, regulating essential services during this crisis caused by Covid-19. (Letter sent to the Minister of Health on 24 March and contact with the Ministry of Science Cabinet throughout the weekend of 28-29 March). The Secretary-General for Health responded to the letter sent to the Minister, ratifying our classification as an essential activity.

On 8 April, we sent a letter to the Spanish Agency of Medicines and Medical Devices to request a post Covid-19 strategy to reduce the impact of the current emergency on clinical trials. That same day, we sent letters to the Ministry of Health and autonomous communities valorising diagnostic tools and tests to scale down the economy and be prepared for new waves in the post-Covid era.  We requested a vision and plan in the middle term making the most of the capacities of the Spanish biotech sector.

On 22 April, we launched a task force of manufacturers of in vitro Covid-19 diagnostic tests and on 13 April, we took part in the panel of judges for the #VenceAlVirus (beat the virus) Hackathon in Madrid.

On 12 May, a resolution was published in the Official Bulletin of Parliament promoting, in coordination with the autonomous communities and cooperation with representatives of healthcare technology and biotechnology companies, the creation of a countrywide strategy for future crises. 

On 1 June, we sent a letter to the Spanish Agency of Medicines and Medical Devices Department of Healthcare Products requesting a meeting to discuss the concerns of the group on personalised medicine and advanced diagnostics regarding the post Covid-19 strategy for in vitro diagnostic tests.

On 5 June, we took a proposal to the Parliament as part of the Workgroup on Public Health and Healthcare, where 34 representatives of the biohealth sector debated the priorities for rebuilding the country after the Covid-19 crisis.